Department of Neurology, Philipps-University Marburg, Marburg, Germany.
Stroke. 2010 Dec;41(12):2918-23. doi: 10.1161/STROKEAHA.110.586826. Epub 2010 Nov 11.
Aneurysmal subarachnoid hemorrhage (SAH) is a cerebrovascular disease with a high mortality rate and severe disability. Longitudinal studies investigating health-economic costs in SAH are scare and only one of them analyzed cost-driving factors. The objective was to evaluate first-year costs in German patients with aneurysmal SAH and to identify independent determinants of costs.
One hundred thirteen incident cases of aneurysmal SAH treated in the Department of Neurosurgery and Neuroradiology at the University of Bonn (catchment area of 500,000 people) between January 2004 and December 2005 were eligible for the study. Cost data were collected using health-economic questionnaires applied at baseline and 6- and 12-month follow-up time. All costs are expressed in (year 2009 values). Clinical assessments were performed using Hunt and Hess scale, Barthel Index, and Rankin Scale. Independent cost-driving factors were determined using multiple regression analysis.
The total first-year costs were 38,300 (95% CI, 34 490 to 43,100) per patient. Direct costs accounted for 58.7% of total costs and were mainly paid by the health insurance (92.0%). Inpatient costs were the main cost component of direct and total costs (42.8% of total costs). The major cost-driving factors of total costs were younger age and worse functional outcome at 12-month follow-up (Barthel Index).
Aneurysmal SAH is a cerebrovascular disease with considerable health-economic burden. Healthcare programs aimed at reducing the burden of SAH on society and individuals should consider cost-driving factors of SAH. Further health-economic studies investigating cost-driving factors of SAH in different countries are needed.
蛛网膜下腔出血(SAH)是一种脑血管疾病,具有高死亡率和严重残疾率。对 SAH 进行健康经济成本的纵向研究很少,只有一项研究分析了成本驱动因素。本研究旨在评估德国蛛网膜下腔出血患者的第一年成本,并确定成本的独立决定因素。
2004 年 1 月至 2005 年 12 月期间,在波恩大学神经外科和神经放射科治疗的 113 例蛛网膜下腔出血患者符合研究条件(覆盖人群 50 万)。在基线和 6 个月及 12 个月随访时使用健康经济问卷收集成本数据。所有成本均以(2009 年价值)表示。临床评估采用 Hunt 和 Hess 量表、Barthel 指数和 Rankin 量表进行。使用多元回归分析确定独立的成本驱动因素。
每位患者第一年的总成本为 38300 欧元(95%CI,34490 至 43100)。直接成本占总成本的 58.7%,主要由医疗保险支付(92.0%)。住院费用是直接和总成本的主要成本组成部分(占总成本的 42.8%)。总费用的主要成本驱动因素是 12 个月随访时年龄较小和功能结局较差(Barthel 指数)。
蛛网膜下腔出血是一种具有相当健康经济负担的脑血管疾病。旨在减轻社会和个人 SAH 负担的医疗保健计划应考虑 SAH 的成本驱动因素。需要进一步在不同国家开展健康经济研究,以调查 SAH 的成本驱动因素。